Sacituzumab govitecan-hziy in 1L mTNBC: ASCENT-03 and ASCENT-04 Studies
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
How do the ASCENT-03 and ASCENT-04 results inform first-line treatment decisions for patients with metastatic triple-negative breast cancer?
James Spellman, NP, MSN, MSSW, MDiv (Gilead Sciences, Inc.), will review the efficacy and safety findings from both Phase 3 studies, with attention to sacituzumab govitecan-hziy–based regimens across PD-L1 status. The session will also examine current unmet needs and how the study results align with NCCN Guidelines® recommendations for first-line treatment selection.
Learning Objectives:
- Describe the current treatment landscape and unmet needs in first-line mTNBC.
- Evaluate efficacy outcomes from the Phase 3 ASCENT-03 and ASCENT-04 studies.
- Assess the safety profiles of sacituzumab govitecan-hziy–based regimens in first-line mTNBC.
- Apply current evidence and NCCN Guidelines® recommendations when selecting first-line treatment across PD-L1 status.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Additional Upcoming Webinars
August 20, 2026 | 2:00 PM
Upcoming Webinar
Introducing a Therapeutic Option in Relapsed/Refractory AML/ALL
August 24, 2026 | 2:00 PM
August 25, 2026 | 2:00 PM